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Effects of target-controlled infusion of high-dose
naloxone on pain and hyperalgesia in a human
thermal injury model: a study protocol
A randomized, double-blind, placebo-controlled, crossover trial
with an enriched design
Anders D. Springborg, MB, BSca,
∗
, Elisabeth K. Jensen, MSa, Bradley K. Taylor, PhDb,
Mads U. Werner, MD, PhDa,
∗
Abstract
Mu-opioid-receptor antagonists have been extensively studied in experimental research as pharmacological tools uncovering
mechanisms of pain modulation by the endogenous opioid system. In rodents, administration of high doses of mu-opioid-receptor
antagonists after the resolution of an inflammatory injury has demonstrated reinstatement of nociceptive hypersensitivity indicating
unmasking of latent sensitization. In a recent human study, pain hypersensitivity assessed as secondary hyperalgesia area (SHA),
was reinstated 7 days after a mild thermal injury, in 4 out of 12 subjects after a naloxone infusion.
The aims of the present study are first, to replicate our previous findings in a larger-sized study; second, to examine if high
sensitizers (subjects presenting with large SHA after a thermal injury) develop a higher degree of hypersensitivity after naloxone
challenge than low sensitizers (subjects presenting with restricted SHA after a thermal injury); and third to examine a dose–response
relationship between 3 stable naloxone concentrations controlled by target-controlled infusion, and the unmasking of latent
sensitization.
Healthy participants (n=80) underwent a screening day (day 0) with induction of a thermal skin injury (47°C, 420seconds, 12.5
cm2). Assessment of SHA was performed 1 and 2hours after the injury. Using an enriched design, only participants belonging to the
upper quartile of SHA (Q4, high sensitizers; n=20) and the lower quartile of SHA (Q1, low sensitizers; n=20) continued the study,
comprising 4 consecutive days—days 1 to 4. Thermal skin injuries were repeated on day 1 and day 3, whereas day 2 and day 4 (7
days after day 1 and day 3, respectively) were target-controlled infusion days in which the subjects were randomly allocated to receive
either naloxone (3.25mg/kg, 4mg/mL) or placebo (normal saline) intravenous. The primary outcome was SHA assessed by
weighted-pin instrument (128mN) 0, 1, 2, and 165 to 169hours after the thermal injury (day 1–4). The secondary outcomes were pin-
prick pain thresholds assessed by weighted-pin instrument (8–512mN) at primary and secondary hyperalgesia areas (days 1–4).
The naloxone-induced unmasking of latent sensitization is an interesting model for exploring the transition from acute to chronic
pain. The results from the present study may provide valuable information regarding future research in persistent postsurgical pain
states.
Abbreviations: LS = latent sensitization, MOR = mu-opioid-receptor, PPT = pin-prick pain threshold, SHA = secondary
hyperalgesia area, TCI = target-controlled infusion, WPI = weighted-pin instrument.
Keywords: enriched design, humans, latent sensitization, naloxone, randomized controlled trial, secondary hyperalgesia, thermal
injury
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1. Introduction
Endogenous opioid analgesia could be impaired or altered in chronic
pain conditions,[1–4] and this may play an important role in the
transition of acute to chronic pain in humans.[5–7] Naloxone and
naltrexone are mu-opioid-receptor (MOR) antagonists and inverse
agonists, often used in experimental research to determine the
contribution of endogenous opioids to the central processing of
pain.[8,9] Naloxone dose-dependently produces either hypoalgesic or
hyperalgesic properties.[10] Recent high-profile studies in rodents
indicate that endogenous MOR analgesia masks latent sensitization
(LS).[11] LS is a silent form of central sensitization, defined as an
increasedresponsivenessof centralnervous system(CNS)nociceptive
neurons to afferent input after tissue injury. LS persists beyond tissue
healing and resolution of hyperalgesia. WhenMOR antagonists are
administered during this resolution phase, we and others have
observed a reinstatement of hypersensitivity to a somato-sensory
stimulus, which we interpret as the unmasking of LS.[5,6,11,12]
Using a randomized, controlled, crossover study design, we
initially reported that an intravenous naloxone dose of 21mg/kg,
delivered 7 days after a mild heat injury, failed to produce
reinstatement of hyperalgesia.[13] In a follow-up study, however,
we found that a higher intravenous dose of 2.0mg/kg did produce
reinstatement of hyperalgesia in 4 out of 12 subjects.[14] The
naloxone-induced hyperalgesia area extended beyond the
primary heat injury area and was therefore termed secondary
hyperalgesia. Compared with the 8 nonresponders, the 4
responders developed larger secondary hyperalgesia areas
(SHAs) in the hours immediately after exposure to the heat injury.
The current study examines 3 important questions. First, are
the results of the 2.0mg/kg study replicable with a greater number
of subjects? Second, is it possible to predict which individuals will
express naloxone-induced reinstatement of hyperalgesia? Third,
is naloxone-induced unmasking of LS a dose-dependent process?
The aims of the present study thus are to: replicate and validate
our previous findings; determine whether “high sensitizers”
express larger hyperalgesia areas after naloxone challenge than
“low sensitizers”, using an enriched design; and examine if the
unmasking process depends on the naloxone concentration,
using a target-controlled infusion (TCI) technique.
2. Methods
2.1. Study management
The study was conducted in accordance with the guidelines and
rules concerning quality control and quality management on
clinical trials involving humans, and followed the Good Clinical
Practice and the Good Manufacturing Practice guidelines. All
data about potential and enrolled participants were treated
confidentially. Only the investigators and relevant authorities had
access to the data and eventual amendments to the protocol were
communicated to the relevant authorities, and the entries on the
registry databases were updated. The study was approved by the
Committee of Health Research Ethics of the Capital Region (H-
15018869), Danish Medicines Agency (2015–005426-19), and
the Data Inspection Authority of the Capital Region (RH-2015-
284, I-suite nr. 04296). The study is registered in EUDRACT
(2015-005426-19) and in ClinicalTrials.gov (NCT02684669).
The approved final protocol version was: Protocol-High-
NxTME_v1.5_ 13.01.2016.
2.2. Participants
The participants were recruited from a registry of participants
previously participating in experimental pain studies at the
Multidisciplinary Pain Center 7612, Neuroscience Center,
Copenhagen University Hospitals (ADS). The participants had
specifically given their verbal or written consent that they may be
contacted in future research. If the investigators experienced
difficulty in recruitment of participants, an advertisement was
placed in a Danish e-site for recruitment of participants in
medical research (forsoegsperson.dk). Additionally, the adver-
tisement was posted on facebook.com and hung up on bulletin
boards at the University of Copenhagen.
The participants received written information about the study
by the investigator (ADS). The investigator then scheduled a
physical meeting with the participant, informing the participant
of the right to bring a relative or a friend for the information
meeting. At the meeting, taking place in an undisturbed
environment, the investigator gave verbal information concern-
ing the study and answered the participant’s and the companion’s
questions. The participant was informed that he had the time to
consider participation in the study. Two days after the meeting,
the investigator called or sent an e-mail, making an appointment
with the participant for the study day.
On the study day, the investigator repeated the verbal
information and answered any questions the participant had.
The written consent was obtained on the study day before any
assessments were done. If the participant needed more time before
signing the informed consent, a new study day was scheduled. The
participant was informed that the participation in the study was
voluntary and that he may withdraw from the study at any time
without further noticeor explanation.This actionwill nothaveany
consequence for ongoing or future medical treatments at the
involved departments or hospitals. Also, the participant was
informed that the investigatormay exclude theparticipant fromthe
study at any time. Participants received an hourly payment for
attending the study of DKK 150 (USD 25), and, if required by the
participant, reimbursement for transportation costs.
2.3. Laboratory environment
The experimental procedures took place at the Multidisciplinary
Pain Center in a quiet, well-lit room [22–25°C; relative humidity
(RH) 20%–45%]. Participants adopted a relaxed recumbent
position during sensory assessments, but were otherwise allowed
to ambulate between assessments. However, during and
immediately after infusion procedures, participants were asked
to adopt a comfortable, recumbent position.
2.4. Study design
A randomized, placebo-controlled, double-blind, crossover
design was used. The study included 1 screening day (day 0)
and 4 experimental days (days 1–4; Fig. 1). Since day 0 was for
selecting the lower quartile (Q1, low sensitizers) and the upper
quartile (Q4, high sensitizers) of the participants, regarding the
area of secondary hyperalgesia developed after a thermal (heat)
injury,[15,16] an enriched design was used. Only participants
belonging to the Q1 or Q4 quartile were included in days 1 to 4.
2.5. Randomization
2.5.1. Low versus high sensitizers. After day 0 (n=80), that is,
the selection into low sensitizers (Q1, n=20) and high sensitizers
(Q4, n=20), a random permutation of numbers from 1 to 40 was
applied (randomization.com). Each low and high sensitizer
received a sequential rank order from 1 to 40 according to the
magnitude of the SHA. These sequential rank numbers were then
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consecutively paired with the list of a random permutation of
numbers, rendering a randomization of the order of low and high
sensitizers. This randomization procedure was performed by the
senior author (MUW; not participating in the assessments),
blinding the examiner to the participant’s Q1 or Q4 affiliation.
2.5.2. Drug allocation. Computer-generated sequence random-
ization, using blocks of 4 subjects (randomization.com), was
performed by Skanderborg Hospital Pharmacy, also responsible
for manufacturing, packaging, and labeling of the drugs. Two
sets of nontransparent sealed envelopes, 1 for each participant,
were prepared. The envelope contained information on treatment
allocation order. The sponsor (MUW) kept one of the sets of
envelopes stored, whereas the other set was kept by the
investigators (ADS, EKJ). Both sets of envelopes were kept in
separate, securely locked, prespecified filing cabinets. Addition-
ally, each drug package included a sealed, nontransparent
envelope containing the appropriate randomization sequence
code, to be broken in case of a medical emergency. The
participants and the investigators were blinded to the treatment
sequence throughout the study. The Skanderborg Hospital
Pharmacy keeps the master randomization list, available for
unblinding after completion of all study data entries.
2.6. Study setup
2.6.1. Day 0. A general algorithm of the study is presented in
Fig. 1. On day 0, participants were asked to sign an informed
consent, meeting the inclusion criteria and affirming the exclusion
criteria (Table 1; ADS, MUW). After a brief medical examination
by the investigator, the Clinical Opiate Withdrawal Scale
(COWS) was completed. Participants were then asked to fill
out psychometric questionnaires, and to complete an online
reaction time test (for details see below). Finally, before inclusion,
a simple drug-screening test for opioids was made. After
inclusion, induction of a thermal skin injury was performed,
and SHAs were assessed (Fig. 2).
As previously presented, further participation depended on the
magnitude of the SHAs developed at day 0: participants
belonging to Q1 or Q4 continued through days 1 to 4, whereas
those belonging to Q2 and Q3 were not included in further
analyses.
2.6.2. Days 1 to 4. On days 1 and 3, thermal injuries were
induced, assessing SHAs (Figs. 1 and 2). On days 2 and 4, TCIs of
naloxone or placebo were administered exactly 7 days after
induction of the thermal injury (Fig. 2). Before the examinations
at day 2 and day 4, the drug-screening tests for opioids were
reiterated.
2.7. Intervention
2.7.1. Target-controlled infusions. The 3-step TCI algorithm
has previously been reported. The algorithm based on pharma-
cokinetic data from the study by Dowling et al[17] was calculated
by the software NONMEM [7.3 ICON Development Solutions,
Manchester, UK (property of UCSF, US)], using computer
simulations based on a population-kinetic model with 2000
simulated administrations distributed on 10 subjects. The
estimated mean (10% and 90% percentiles) plasma concen-
trations of naloxone at each TCI step are illustrated in Fig. 3. A
total dose of 3.25mg/kg of naloxone (4mg/mL) vis-á-vis 0.81mL/
kg of placebo (normal saline) was administered in a stepwise
approach (Table 2). Each step contained a 1-minute bolus and a
24-minute infusion. During the last 10minutes of each step,
plasma concentrations were considered to be stable, and
therefore the pharmacodynamic assessments were performed
(Fig. 3). The infusion was to be discontinued at any step if the
participant’s pain ratings at rest ≥5, assessed by the numerical
rating scale (NRS: 0=no pain, 10=worst possible pain
imaginable).
Two syringes (BD Perfusion syringe: Becton, Dickinson and
Company Limited, Louth, Ireland) were each be filled with a 50-
mL solution of either naloxone or placebo and inserted into a
syringe-based pump (Perfusor Space Infusion System 8713030:
B. Braun Melsungen AG, Melsungen, Germany).
2.7.2. Rescue drugs. Epinephrine 1mg/mL, and other relevant
drugs and equipment for cardiopulmonary resuscitation were
Figure 1. General study layout: thermal injuries are induced on day 0 and day
1, and on day 3. Day 0 is a screening day, uncovering low sensitizers [small
secondary hyperalgesia areas: lower quartile (Q1)] and high sensitizers [large
secondary hyperalgesia areas: upper quartile (Q4)]. Day 1 and day 3 include
induction of thermal injuries in high and low sensitizers. Target-controlled-
infusion (TCI) days are day 2 and day 4, with randomized allocation between
placebo and naloxone. The timeline between day 1 and day 2, and between
day 3 and day 4, is 7 days. The timeline between day 0 and day 3 is>8 weeks.
Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Healthy male Participant does not speak or
understands Danish
Age above 18 y and below 35 y Participant cannot cooperate with the
investigation
Signed informed consent Allergic reaction against morphine or
other Opioids (incl. naloxone)
Urine sample without traces of opioids Alcohol or drug abuse
ASA I Use of psychotropic drugs (exception of
SSRI)
Body mass index (BMI):
18 <BMI<30kg/m2
Neurologic or psychiatric disease
Signs of neuropathy in the examination
region
Previous severe trauma to the lower legs
with sequelae
Scarring or tattoos in the examination
region
Chronic pain condition
Regular use of analgesic drugs
Use of prescription drugs one week
before the trial
Use of over-the-counter (OTC) drugs 48h
before the trial
Does not develop measureable secondary
hyperalgesia areas after BI
ASA=American Society of Anesthesiology (physical status classification system), BI=burn injury,
BMI=body mass index, SSRI= selective serotonin reuptake inhibitors.
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available. An anesthesiologist (MUW) on call, dedicated to the
study, resided in a room adjacent to the laboratory and was
instantly available at all times during the study.
Midazolam 1mg/mL and alfentanil 0.5mg/mL were available
for management of agitation and anxiety, and for the treatment
of severe acute pain, respectively. Other drugs that the
investigator considered necessary for the management of adverse
effects (atropine, ondansetron) were administered as needed. The
administration of rescue drugs was recorded in the participant’s
Case Report Form.
2.8. Monitoring
On TCI days (days 2 and 4), the participants were continuously
monitored with 3-lead ECG, heart rate, and pulse oximetry, and
noninvasive blood pressure and respiratory rate were regularly
assessed. Monitoring started before infusion and ended 1hour
40minutes after the start of infusion. Other signs of adverse
effects, for example, epigastric pain, headache, lethargy, nausea,
and photophobia, were reported in the Case Report Form.
2.9. Questionnaires
2.9.1. Clinical Opiate Withdrawal Scale. The COWS is a an
examiner-based scale evaluating signs of opioid withdrawal.[19]
Quantitative assessments of heart rate changes, diaphoresis,
restlessness, pupil size, bone or joint aches, running nose or
tearing, nausea, vomiting, diarrhea, tremor, yawning, anxiety or
irritability, and “goose-flesh" were categorized into 11 catego-
ries. COWS scores were graded as follows: 5 to 12=mild; 13 to
24=moderate; 25 to 36=moderately severe; >36= severe.
2.9.2. The Hospital Anxiety and Depression Scale. The
Hospital Anxiety andDepression Scale (HADS) evaluates anxiety
and signs of depression[20,21] based on 14 questions about the
subject’s status in the previous week (each subscale contains 7
questions). Participants rated each question on a scale of 0 to 3.
The 2 subscales were summed separately. The maximum score on
each subscale was 21 points, and a score of 11 or more points
suggested that the participant likely or definitely was suffering
from anxiety or depression. In the case of score >11 points in the
depression subscale of the HADS, a physician decided if there are
clinical signs of depression. If there were signs of depression, the
diagnosis was disclosed to the participant. The participant was
informed that the diagnosis of depression was based on clinical
judgment (the HADS scale can be included in the diagnostic
procedure). If it is the participant’s wish, he should visit his
general practitioner for diagnosis and eventual treatment.
Participants with significant signs of depression were excluded
from the study.
2.9.3. The Pain Catastrophizing Scale. The Pain Catastroph-
izing Scale (PCS) consists of 13 questions divided into 3 sections:
rumination, exaggeration, and helplessness.[22] The answers were
rated on an ordinal scale (0 to 4 points) and summed. Sign of pain
catastrophizing was a total score >30 points.
Figure 2. Day 1/day 3 (cf. Fig. 1) includes baseline assessments (green rectangle, 0minute), induction of a thermal injury (TI, red rectangle, 20minutes), and
postinjury assessments (blue rectangles: 1hour 27minutes and 2hours 27minutes). Day 2/day 4 (cf. Fig. 1) includes a predrug assessment (magenta rectangle;
postinjury 165hours), drug infusions (naloxone or placebo; 167hours 35minutes; 168hours 0minute; 168hours 25minutes) and assessments during target-
controlled infusion [(TCI); grey rectangles]. The estimated TCI plasma concentrations are superimposed in dashed red line. Numbers (1–3) during the infusion period
indicate the 3 TCI steps. Timelines for assessments of pin-prick pain thresholds are indicated by red stars, and secondary hyperalgesia areas by green stars.
Figure 3. Test algorithm day 2/day 4 with superimposed naloxone plasma–-
concentration curves. Median plasma concentration (red) with 10% and 90%
percentiles ranged (dashed black lines) during a 3-step target-controlled
infusion (TCI). Naloxone is given at step 1 (S1: 15–25minutes) with 0.25mg/kg,
step 2 (S2: 39–49minutes) 0.75mg/kg, and step 3 (S3: 65–75minutes) 2.25
mg/kg. Yellow timelines represent ratings with Clinical Opiate Withdrawal Scale
(COWS) and blue columns indicate sensory testing (BL and S1–3: secondary
hyperalgesia areas; BL and S3: pin-prick pain thresholds). BL=baseline
assessments (reproduced with permission from trials).[18]
Springborg et al. Medicine (2016) 95:46 Medicine
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2.10. Sensory assessments
2.10.1. Online reaction time.Online reaction timewas based on
a free-ware computer application showing a red-green traffic
light.[23] Participants were instructed to press the button when the
light changed from red to green, and the reaction time in
milliseconds was indicated. Three measurements were obtained,
and the median value was used as a representative estimate of
reaction time.
2.10.2. Thermal injury. An area 2.55.0cm2 with the longi-
tudinal (large) axis pointing cephalad was outlined by a marker
on the medial aspect of the lower leg with the upper margin 11cm
below the medial meniscus and the anterior border 7cm from the
anterior margin of the tibia.[13] The participants were instructed
to use a hair trimmer in the assessment area 2 days before the
study, to avoid any interference with the sensory assessments. In
case of inadequate trimming, the investigator removed any hair in
the assessment area using a surgical hair trimmer (Surgical
Clipper 9681, 3M Healthcare, MN). Day 0, day 1, and day 3
first-degree thermal injuries were induced in the area by a
computerized contact thermode (MSA Thermal Stimulator,
Somedic AB, Hörby, Sweden; 5.02.5cm2; baseline: 32°C;
ramp rate: + 1°C/s; plateau: 47°C; duration: 420seconds) applied
with gentle pressure (as previously described).[24,25] During the
thermal injury, pain assessments (NRS) were made at 0, 30, 60,
120, 180, 240, 300, 360, and 420seconds.
2.10.3. Assessment of secondary hyperalgesia areas. Areas
of secondary hyperalgesia were assessed by a weighted-pin
instrument (WPI; 128mN corresponding to 2.606kPa; MRC
Systems, Heidelberg, Germany)[24] delivering punctate stimuli
(stimulus area: 0.049mm2) on day 0, day 1, and day 3: before,
and 1 and 2hours after the thermal injury (Figs. 1–2); and day 2
and day 4: 165 to 169hours after the thermal injury (baseline:
165hours 0minute; during TCI: 167hours 35minutes, 168hours
0minute, and 169hours 25minutes). The borders of the SHAs
were determined by stimulating along 8 symmetric lines
converging towards the center of the thermal injury. The
punctate stimulations started in normal skin outside the area
of secondary hyperalgesia and continued inwards towards the
thermal injury area, applying a velocity of 0.5cm/s and a
stimulation rate of 0.7 to 1.0Hz. The participant was asked, with
eyes closed, to report when the punctate sensation changed from
an innocuous pin-prick to a stinging, smarting, or unpleasant
sensation. When the change was reported, the weighted pin was
moved 1 step further in the inward trajectory and the participant
had to confirm that the change persisted. If the change was
confirmed, the location of the first punctate stimulus was marked
on the skin, indicating 1 corner of the delineated octagon. If not
confirmed, the punctate stimulation trajectory continued until
perceptual changes in 2 consecutive punctate stimuli were
obtained. The secondary hyperalgesia markings were transferred
to a clear acetate sheet, and the octagon area was calculated by
planimetry using a vector-based drawing program (Canvas 12.0,
ACD Systems International, BC, Canada).
If SHAs were delineated at baselines (day 0, day 1, or day 3) or
165hours after injury (Fig. 2; day 2 or day 4), the participants
were asked to compare these perceptions to postinjury sensations
(day 0, day 1, or day 3) or sensations during TCI (day 2 or day 4),
in regard to quality (stinging, smarting, or unpleasant sensation)
and intensity. If the sensations were more stinging, smarting, or
unpleasant, and of a higher intensity in the postinjury phase, then
the baseline and postinjury 165-hour sensations were not
considered to reflect genuine SHAs. If no perceptual difference
was registered, the baseline and postinjury 165-hour assessments
were substracted from the area measured after the thermal injury
and during the TCI regimen, respectively.
2.10.4. Pin-prick pain thresholds. Pin-prick pain thresholds
(PPTs) were assessed by the WPIs (8, 16, 32, 64, 128, 256, 512
mN) using a modified Dixon procedure, both in the primary
thermal injury area and in the SHA[26,27] (Fig. 2). PPTs were
assessed on day 0/day 1/day 3 (baseline, 1, and 2hours
postinjury) and day 2/day 4 [postinjury: 165hours 0minute
and 168hours 25minutes (step 3 of TCI)]. Assessment of PPT
was not performed during the first and second step of the TCI,
due to the risk of development of sensitization, possibly
confounding study results. All assessments were performed
while the participant had closed eyes. The WPIs were applied
each, 5 times perpendicularly to the skin, at a rate of 0.7 to 1.0
Hz, using a randomized distribution pattern, first in the primary
injury area and then in the SHA. If no SHA was present, the
punctate stimuli were applied in an area 5cm outside the
perimeter of the primary injury area. The WPI with the lowest
punctate force yielding 3 or more stinging, smarting, or
unpleasant sensations indicated the threshold. An ordinal scale
was used (1=8mN, 2=16mN, 3=32mN, 4=64mN, 5=128
mN, 6=256mN, 7=512mN, 8:>512mN). Themedian value of
the 5 assessments indicated the PPT.
2.11. Outcome
2.11.1. Primary outcome. The primary outcome was SHAs
assessed by a WPI (128mN) 0, 1, 2, and 165 to 169hours after
the thermal injury (days 1–4).
2.11.2. Secondary outcomes. The secondary outcomes were
PPTs assessed by WPIs (8–512mN) at primary and SHAs (days
1–4).
2.11.3. Tertiary outcomes. Tertiary outcomes were pain ratings
(NRS) during thermal injury (day 1 and day 3), HADS (day 0),
PCS (day 0), COWS (day 2 and day 4), online reaction time
(days 1–4).
2.12. Sample size calculation
Data from our previous high-dose naloxone study[14] in high
sensitizers (n=3; Q4), 168hours after the thermal injury,
indicated mean (SD) values of SHAs during placebo infusion
of 2.1cm2 (2.5cm2), and during naloxone infusion 111.0cm2
(26.3cm2). Corresponding data for the low sensitizers (n=3; Q1)
were during placebo infusion 0.3cm2 (0.1cm2) and during
naloxone infusion 0.9cm2 (0.6cm2). Using a significance level of
0.01 (a) and a power of 0.90 (b=0.10), the estimated number of
Table 2
Target-controlled infusion (TCI) of naloxone.
Step TCI Time, min Dose, mg/kg
Step 1 Bolus 1 0–1 0.02
Infusion 1 1–25 0.23
Step 2 Bolus 2 25–26 0.06
Infusion 2 26–50 0.69
Step 3 Bolus 3 50–51 0.18
Infusion 3 51–75 2.07
Total 75 3.25
Target-controlled infusion (TCI) of naloxone (4mg/mL): timeline and dose/kg for the 3 steps: step 1
(bolus 1+ infusion 1); step 2 (bolus 2+ infusion 2); step 3 (bolus 3+ infusion 3).
Springborg et al. Medicine (2016) 95:46 www.md-journal.com
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individuals needed to reject the null hypothesis in the high
sensitizers were 5 (effect size 4.3) and in the low sensitizers were
18 (effect size 1.1) (G∗Power3.9.1.2, Kiel University, Germany).
However, because the data used for sample size estimates were
provided by an extremely limited number of individuals, and,
because the nature of the study also was proof of concept, it was
decided to include 20 high sensitizers and 20 low sensitizers (as
previously mentioned using an enriched design, based on a
screening day 0 of 80 subjects). Boot-strapping techniques could
have been used, but we considered the number of individuals used
in the sample to estimate too extreme. On the other hand, if a
larger number of subjects were needed, the clinical significance
was deemed of dubious value.
2.13. Statistics
To test if data were normally distributed, residual plots and the
Kolmogorov–Smirnov test were used (SPSS IBM Software 22.0,
Chicago, IL; MedCalc Software: version 16.4.3, Mariakerke,
Belgium). In the case of non-normal data distribution, an attempt
for normalization of data was applied, either using logarithmic
transformation or a Box-Cox transformation.[28]
A mixed model with random effect for subject and fixed effects
for the variables sensitizers (high sensitizers/low sensitizers),
intervention (naloxone/placebo), TCI (step 1/step 2/step 3), and
PCS scores were used for the primary outcome secondary
hyperalgesia. Nonsignificant (P>0.05) factors, beginning with
interactions, were excluded until all included factors attained
significance. Main effects and interaction effects were examined.
For sake of clarity, conventional comparisons of SHAs, using
simple calculation of the principal differences, are shown below.
Statistics were by paired and unpaired t tests, or Mann–Whitney
and Wilcoxon tests, depending on data distribution.
DSHAQ4 ¼ SHANX Q4  SHAPLQ4
DSHAQ1 ¼ SHANX Q1  SHAPLQ1
DSHA ¼ SHAQ4  SHAQ1
where SHA= secondary hyperalgesia areas; Q1=belonging to
the lower quartile; Q4=belonging to the upper quartile; NX=
naloxone; and PL=placebo. The maximal SHA values during the
TCI (irrespective of TCI step) are used.
The risks of type I (a) and type II (b) errors were set to 0.01 and
0.10, respectively. Statistical calculations were performed
initially with partially unblinded data, that is, groups A and B.
When these statistic calculations had been completed, treatment
allocations were fully unblinded into naloxone and placebo
groups. Intention-to-treat (ITT) and per-protocol (PP) data were
analyzed separately.
3. Safety issues
3.1. Thermal injury
The first-degree thermal injury is a validated pain model.[29] The
induction of the injury is a moderately painful procedure, but not
associated with spontaneous pain after termination of the heat
stimulus. Morphologically, the injury is comparable to a slight
sunburn leading to localized erythema, edema, hyperalgesia, and
hypersensitivity. These signs and symptoms subside in most cases
24 to 48hours after the injury, without leaving residual signs.
However, in 1% to 2%of participants, late hyperpigmentation in
the area is evident.
If the participant experiences severe pain during induction of
the thermal injury, the participant is able to discontinue the
heating by pushing a button terminating the stimulus or by saying
so to the investigator. Occurrence of a more severe second to
third-degree thermal injury has been described following the
use of a malfunctioning, overheating contact thermode. Due to
the rigorous, compulsory testing paradigms of our thermodes, we
have not experienced any thermal adverse effects during the past
5 years with the thermal injurymodel (H-2-2010-115; H-2-2012-
036; H-2-2012-174; H-1-2013-045; H-4-2013-013), including
more than 500 experimental thermal injuries.
3.2. Development of a sustained pain state due to the
high-dose naloxone
With regard to the risk of development of a sustained or even
persistent pain state after the naloxone administration after the
thermal injury, the authors considered it highly unlikely. First, the
thermal injury results in a transient pain perception. Second,
naloxone does not affect the production of endogenous opioids,
but only acts as a short-acting reversible antagonist of opioids.
Third, in adults, the elimination (T½b) half-life of naloxone is
54 to 64minutes.[30,31] Naloxone has no known long-acting
metabolites and thus there are no pharmacokinetic reasons for a
prolonged reversal of endogenous opioids. Fourth, in rodent
studies, administration of MOR antagonists has caused
transient episodes of hypersensitivity with a duration of 60 to
90minutes.[11] Reiterated administration of naltrexone, over
the course of months, has confirmed full reversibility of the
hypersensitivity episodes. Fifth, in our recent study with
intravenous (i.v.) administration of naloxone 2.0mg/kg, very
short-lasting changes in hypersensitivity were seen in 4 out of the
12 individuals responding to naloxone.[14] Thus, the authors
consider the occurrence of sustained pain to be highly unlikely in
this study.
3.3. Naloxone dose considerations
The current study used a naloxone dose of 3.25mg/kg, which is
600 to 6000 times higher than clinical doses used in the treatment
of a severe opioid overdose.[32] Furthermore, a positron emission
tomography (PET) study from 1989 indicated that administra-
tion of 0.1mg/kg naloxone resulted in complete inhibition of
[11C]-carfentanil binding to MOR in humans.[33] Thus, we use a
naloxone dose that is approximately 33 times the dose required to
occupy all MORs.
The dose selection was determined with two rationales in
mind. First, over the course of our previous study to back-
translate the human thermal injury model to a rodent model, it
was revealed that doses of 3.0 to 10.0mg/kg of naloxone,
delivered 21 days after heat injury to the skin of the plantar
hindpaw, were required to precipitate reinstatement of hyper-
sensitivity.[11]Second, in our previous human studies in the heat
injury model, low-dose naloxone infusion (21mg/kg)[13] did not
reinstate secondary hyperalgesia, whereas high-dose naloxone
infusion (2.0mg/kg) did precipitate reinstatement in 4 out of 12
subjects.[14]
Regarding the toxicity profile, previous studies have shown
that systemic doses up to 6.0mg/kg have been tolerated well
in healthy participants,[34–39] and even in higher doses in
patients[40–45] with none or only mild to moderate transient
adverse effects. However, no methodical evaluation of adverse
effects has been performed in these studies. In our previous study
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including 3 pilot participants and 12 study participants, 6
subjects reported mild transient adverse effects, including
tiredness, epigastric pain, frontal headache, and photophobia.
Furthermore, naloxone did not induce any changes in ECG,
blood pressure, heart rate, respiratory rate, or oxygen saturation
during the experimental days.
In the present study, the unmasking of LS is to be generated
with TCI, acquiring 3 successively higher plasma concentration
levels of naloxone, a precautionary measure that may reveal
adverse effects necessitating discontinuation of the infusion at an
early stage. Additionally, the TCI technique may confirm a
pharmacodynamic dose–response relationship for LS. In conclu-
sion, the authors, therefore, consider it safe to administer a
naloxone dose of 3.25mg/kg in the present study.[30,31]
4. Implications of the study
Provided that the study outcome replicates our initial findings, it
will highlight several important pathophysiological issues. Exten-
sive tissue injury sensitizes CNS neurons by increasing excitability
and synaptic efficiency.[46,47] A prominentmanifestation of central
sensitization is development of secondary hyperalgesia, where
innocuous repetitive or dynamic stimuli in normal tissue
surrounding the injured area lead to the triggering of a nociceptive
response. Previous reports indicate that MOR antagonists can
reinstate hyperalgesia after the resolution of the injured area,
suggesting that central sensitization may reside in a silent form,
known as LS.[11,14] Although it is generally believed that central
sensitization is implicated in a number of chronic pain states,[46] it
has been hypothesized that unmasking of LS is a principal
mechanism driving the transition from acute to the chronic pain
state.[6,11] The current protocol is designed to provide proof of
concept for LS in humans in an experimental pain model. This
study is a significant step forward todetermine themanifestation of
LS in clinical postsurgical models, for example, groin hernia repair
or dental extraction.[48] Severe persistent postsurgical pain affects
2% to 10% of patients depending on the type of surgery, surgical
technique, and patient-related factors, and is a huge and daunting
problem for the individual and the society.[49,50] The suggested
clinical studies could help improve our understanding of the
postsurgical chronification process.
In a hallmark study on central sensitization, Clifford Woolf
stated: “an important question that still needs to be determined is
whether there are individuals with a higher inherited propensity
for developing central sensitization than others, and if so,
whether this conveys an increased risk in both developing
conditions with pain hypersensitivity, and their chronifica-
tion.”[47] This is clearly an important research issue. The present
study may shed light on the role of the sensitization phenotype
and enable prediction of the response to naloxone-induced
reinstatement with the use of an enriched design. This design
distributes participants as high sensitizers or low sensitizers
(subjects presenting with large or small SHA, respectively, after a
thermal injury). We anticipate that high sensitizers will more
consistently develop reinstatement of hypersensitivity as com-
pared with low sensitizers. If so, then this enriched design may be
used in future clinical and basic science research to elucidate
markers of vulnerability to chronic postsurgical pain.[14]
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